<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Med</journal-id><journal-id journal-id-type="publisher-id">pmed</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15783261</article-id><article-id pub-id-type="pmc">PMC1069668</article-id><article-id pub-id-type="doi">10.1371/journal.pmed.0020077</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence and Other Communications</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cancer Biology</subject><subject>Immunology</subject><subject>Infectious Diseases</subject><subject>Allergy/Immunology</subject><subject>Anesthesiology</subject><subject>Oncology</subject></subj-group><subj-group subj-group-type="System Taxonomy"><subject>Oncology</subject><subject>Immunology and allergy</subject><subject>Infectious Diseases</subject></subj-group></article-categories><title-group><article-title>Tumor Cell Recognition Efficiency by T Cells</article-title><alt-title alt-title-type="running-head">Correspondence</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Speiser</surname><given-names>Daniel E</given-names></name><xref ref-type="corresp" rid="n1"/></contrib><contrib contrib-type="author"><name><surname>Cerottini</surname><given-names>Jean-Charles</given-names></name></contrib><contrib contrib-type="author"><name><surname>Romero</surname><given-names>Pedro</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><institution>Ludwig Institute for Cancer Research</institution><addr-line>Lausanne</addr-line><country>Switzerland</country></aff><author-notes><corresp id="n1">E-mail: <email>daniel.speiser&#x00040;hospvd.ch</email></corresp><fn id="n2" fn-type="COI-statement"><p>
<bold>Competing Interests:</bold> The authors have declared that no competing interests exist.</p></fn></author-notes><pub-date pub-type="ppub"><month>3</month><year>2005</year></pub-date><pub-date pub-type="epub"><day>29</day><month>3</month><year>2005</year></pub-date><volume>2</volume><issue>3</issue><elocation-id>e77</elocation-id><permissions><copyright-statement>Copyright: &#x000a9; 2005 Speiser et al.</copyright-statement><copyright-year>2005</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><related-article id="d35e118" related-article-type="companion" ext-link-type="doi" xlink:href="10.1371/journal.pmed.0010028" xlink:title="research article" vol="2" page="e28">
<article-title>Diversity and Recognition Efficiency of T Cell Responses to Cancer</article-title>
</related-article><related-article id="d35e123" related-article-type="companion" ext-link-type="doi" xlink:href="10.1371/journal.pmed.0020095" xlink:title="correspondence" vol="2" page="e95">
<article-title>Authors' Reply</article-title>
</related-article></article-meta></front><body><p>Stuge et al. report a detailed analysis of the fine specificity of CD8&#x0002b; T cells against tumor-associated antigen in melanoma patients [<xref rid="pmed-0020077-b1" ref-type="bibr">1</xref>]. They compared peptide-vaccination-driven with naturally arising T cell responses against the HLA-A&#x0002a;0201 restricted melanoma peptide antigens M26 (derived from Melan-A/MART-1) and G209-2M (derived from gp100 protein). A major endpoint of this study was in vitro tumor cell recognition by T cells. Fortunately, this is increasingly used as a &#x0201c;golden&#x0201d; standard in the assessment of tumor-specific T cells. The authors suggest that spontaneously arising antigen-specific T cell populations are qualitatively different from those induced by vaccination with heteroclitic peptides (which are altered for increased HLA binding): tumor cell recognition was found in nearly all T cells from the former, but only in a minority from the latter. As reported previously, these results correlated with recognition efficiency of antigenic peptides. We agree that this has considerable implications for immunotherapy and congratulate the authors for analyzing T cell recognition in great detail. However, in one point our own studies lead to different results: we repetitively found that the majority of T cells generated with the heteroclitic Melan-A M26 peptide were tumor reactive. This was the case for Melan-A-specific T cell populations generated in HLA-A&#x0002a;0201 transgenic mice [<xref rid="pmed-0020077-b2" ref-type="bibr">2</xref>], in vitro [<xref rid="pmed-0020077-b3" ref-type="bibr">3</xref>], and in melanoma patients [<xref rid="pmed-0020077-b4" ref-type="bibr">4</xref>]. The latter studies also assessed T cells from vaccination-site sentinel lymph nodes, containing T cells that are very likely selected and activated by vaccination and not by the tumor.</p><p>The authors point out correctly that tetramer&#x0002b; T cells comprise many cells unable to recognize and kill tumor cells in an antigen-specific manner, presumably owing to low T cell receptor avidity to cognate antigen. An extreme case is na&#x000ef;ve T cell populations, of which the majority are unable to recognize tumor cells, despite their specific binding to MHC/ peptide tetramers [<xref rid="pmed-0020077-b5" ref-type="bibr">5</xref>]. Therefore, it is crucial to exclude na&#x000ef;ve T cells from studies analyzing tumor recognition. HLA-A&#x0002a;0201&#x0002b; humans (healthy individuals and melanoma patients) have 0.07&#x00025; &#x000b1; 0.05&#x00025; na&#x000ef;ve Melan-A tetramer&#x0002b; cells within peripheral blood CD8&#x0002b; T cells [<xref rid="pmed-0020077-b5" ref-type="bibr">5</xref>,<xref rid="pmed-0020077-b6" ref-type="bibr">6</xref>]. The three patients studied by Stuge et al. had 0.23&#x00025;, 0.12&#x00025;, and 0.50&#x00025; Melan-A tetramer&#x0002b; cells. Thus, one can estimate that the studied populations from the three patients contained approximately 30&#x00025;, 60&#x00025;, and 15&#x00025; na&#x000ef;ve Melan-A-specific T cells, respectively. This is only a rough estimate&#x02014;tetramer analysis before vaccination and assessment of CD45RA/ CCR7 expression would give more insight. Nevertheless, it remains likely that the first two patients had considerably more na&#x000ef;ve cells than the third patient (i.e., the one without immunotherapy). In addition, na&#x000ef;ve-derived CD8&#x0002b; T cells have a higher clonogenic potential than activated Melan-A-specific T cells from melanoma patients (unpublished data). This means that overrepresentation of clones derived from na&#x000ef;ve CD8&#x0002b; T cells is likely to occur when both na&#x000ef;ve and activated antigen-specific CD8&#x0002b; T cells co-exist in a given lymphocyte population. As mentioned, Stuge et al. found unexpected high frequencies of T cell clones not recognizing tumor cells in the two vaccinated patients. It is conceivable that this was due to the presumably high percentages of na&#x000ef;ve Melan-A-specific cells present in the populations used for generating the clones, which would provide an explanation for the discrepancy with the results of our studies [<xref rid="pmed-0020077-b2" ref-type="bibr">2</xref>,<xref rid="pmed-0020077-b3" ref-type="bibr">3</xref>,<xref rid="pmed-0020077-b4" ref-type="bibr">4</xref>].</p><p>Ethical considerations limit vaccination studies in healthy humans. In patients, candidate antigens should therefore be tested with strong adjuvants [<xref rid="pmed-0020077-b7" ref-type="bibr">7</xref>], to increase the likelihood that the studied responses are predominantly vaccination-driven, with only minor contribution of spontaneous T cell activation [<xref rid="pmed-0020077-b8" ref-type="bibr">8</xref>]. It would be desirable to directly compare vaccination with heteroclitic peptide versus vaccination with natural peptide. However, this is hampered by the lack of ex vivo detectable responses to native peptides owing to their low immunogenicity. Another option is to analyze clonal distributions (T cell receptors) of responding T cells extensively: Further support for the notion that spontaneous (tumor driven) responses have increased potential for tumor recognition would be obtained if mono/oligoclonal T cell repertoires are indeed significantly more often found in spontaneous than vaccination-induced responses.</p><p>We certainly agree that vaccines must be optimized. Thus, more such studies are desirable, since they have high potential to lead to better understanding of the differences between clinically irrelevant and relevant T cell responses, and to rapidly identify the most promising vaccine formulations that can subsequently be tested in large-scale clinical trials.</p></body><back><fn-group><fn id="n3" fn-type="other"><p>
<bold>Citation:</bold> Speiser DE, Cerottini JC, Romero P (2005) Tumor cell recognition efficiency by T cells. PLoS Med 2(3): e77.</p></fn></fn-group><ref-list><title>References</title><ref id="pmed-0020077-b1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuge</surname><given-names>TB</given-names></name><name><surname>Holmes</surname><given-names>SP</given-names></name><name><surname>Saharan</surname><given-names>S</given-names></name><name><surname>Tuettenberg</surname><given-names>A</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Diversity and recognition efficiency of T cell responses to cancer</article-title><source>PLoS Med</source><year>2004</year><volume>1</volume><fpage>e28</fpage><pub-id pub-id-type="pmid">15578105</pub-id></element-citation></ref><ref id="pmed-0020077-b2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Men</surname><given-names>Y</given-names></name><name><surname>Miconnet</surname><given-names>I</given-names></name><name><surname>Valmori</surname><given-names>D</given-names></name><name><surname>Rimoldi</surname><given-names>D</given-names></name><name><surname>Cerottini</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A&#x0002a;0201/Kb transgenic mice</article-title><source>J Immunol</source><year>1999</year><volume>162</volume><fpage>3566</fpage><lpage>3573</lpage><pub-id pub-id-type="pmid">10092815</pub-id></element-citation></ref><ref id="pmed-0020077-b3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valmori</surname><given-names>D</given-names></name><name><surname>Fonteneau</surname><given-names>JF</given-names></name><name><surname>Mara&#x000f1;&#x000f3;n Lizana</surname><given-names>C</given-names></name><name><surname>Gervois</surname><given-names>N</given-names></name><name><surname>Li&#x000e9;nard</surname><given-names>D</given-names></name><etal/></person-group><article-title>Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogs</article-title><source>J Immunol</source><year>1998</year><volume>160</volume><fpage>1750</fpage><lpage>1758</lpage><pub-id pub-id-type="pmid">9469433</pub-id></element-citation></ref><ref id="pmed-0020077-b4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayyoub</surname><given-names>M</given-names></name><name><surname>Zippelius</surname><given-names>A</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name><name><surname>Rimoldi</surname><given-names>D</given-names></name><name><surname>Valmori</surname><given-names>D</given-names></name><etal/></person-group><article-title>Activation of human melanoma reactive CD8&#x0002b; T cells by vaccination with an immunogenic peptide analog derived from Melan-A/MART-1</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>669</fpage><lpage>677</lpage><pub-id pub-id-type="pmid">12576434</pub-id></element-citation></ref><ref id="pmed-0020077-b5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zippelius</surname><given-names>A</given-names></name><name><surname>Batard</surname><given-names>P</given-names></name><name><surname>Rubio-Godoy</surname><given-names>V</given-names></name><name><surname>Bioley</surname><given-names>G</given-names></name><name><surname>Lienard</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>2865</fpage><lpage>2873</lpage><pub-id pub-id-type="pmid">15087405</pub-id></element-citation></ref><ref id="pmed-0020077-b6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>P</given-names></name><name><surname>Valmori</surname><given-names>D</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name><name><surname>Zippelius</surname><given-names>A</given-names></name><name><surname>Rimoldi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma</article-title><source>Immunol Rev</source><year>2002</year><volume>188</volume><fpage>81</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">12445283</pub-id></element-citation></ref><ref id="pmed-0020077-b7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speiser</surname><given-names>DE</given-names></name><name><surname>Li&#x000e9;nard</surname><given-names>D</given-names></name><name><surname>Rufer</surname><given-names>N</given-names></name><name><surname>Rubio-Godoy</surname><given-names>V</given-names></name><name><surname>Rimoldi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Rapid and strong human CD8&#x0002b; T cell responses to vaccination with peptide, IFA and CpG oligodeoxynucleotide 7909</article-title><source>J Clin Invest</source><year>2005</year><comment>In press</comment></element-citation></ref><ref id="pmed-0020077-b8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speiser</surname><given-names>DE</given-names></name><name><surname>Rimoldi</surname><given-names>D</given-names></name><name><surname>Batard</surname><given-names>P</given-names></name><name><surname>Li&#x000e9;nard</surname><given-names>D</given-names></name><name><surname>Lejeune</surname><given-names>F</given-names></name><etal/></person-group><article-title>Disease-driven T cell activation predicts immune responses to vaccination against melanoma</article-title><source>Cancer Immunity</source><year>2003</year><volume>3</volume><fpage>12</fpage><pub-id pub-id-type="pmid">12962476</pub-id></element-citation></ref></ref-list></back></article>
